GERON CORP
No SEC Form 4 filings for $GERN in the last 30 days.
Geron (NASDAQ:GERN) said about 8,000 U.S. patients may be eligible for RYTELO in second-line, lower-risk MDS. The company guided 2026 RYTELO net product revenue to the mid-to-high end of $220 million to $240 million and expects operating expenses of $230 million to $240 million. Q2 gross-to-net deductions rose to 20.7%.
Geron (GERN) reported Q2 2026 results, citing RYTELO (imetelstat) net product revenue of $57.5M, up 17% YoY. Net loss was $16.7M, slightly wider than $16.4M. Cash and marketable securities totaled $327M at June 30. For FY 2026, Geron guided RYTELO revenue of $220M to $240M and operating expenses of $230M to $240M. Wedbush reiterated an outperform rating and set a $6 price target.
GERON CORP (GERN) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 d158179dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Geron Corporation Reports Second Quarter 2026 Financial Results and Recent Business Highlights August 5, 2026 Achieved $57.5 million in RYTELO ® (imetelstat) net product revenue in Q2 2026, an increase of 11% compared to Q1
Over the past 7 days, alphai's AI scored 7 news stories mentioning GERN (GERON CORP). Coverage has skewed bullish: 6 bullish, 1 neutral, and 0 bearish.
Recent GERN coverage spans earnings, financial news and market movers.
The call provides updated full-year revenue positioning plus margin and gross-to-net trajectory, which can drive near-term valuation and trade positioning.
RYTELO growth and reiterated revenue guidance are the core near-term drivers for GERN’s valuation and risk profile.
Guidance and quarterly RYTELO demand metrics provide a near-term earnings power check for GERN’s hematology franchise.
RYTELO commercialization progress plus maintained 2026 product revenue and opex guidance is the core near-term driver for GERN positioning.
RYTELO demand and the updated 2026 revenue range are the core drivers for the move.
alphai scores every news story that mentions GERN with an AI model for sentiment and relevance, and aggregates insider trades from GERON CORP's SEC EDGAR Form 4 filings. Figures refresh continuously.
Geron (NASDAQ:GERN) said about 8,000 U.S. patients may be eligible for RYTELO in second-line, lower-risk MDS. The company guided 2026 RYTELO net product revenue to the mid-to-high end of $220 million to $240 million and expects operating expenses of $230 million to $240 million. Q2 gross-to-net deductions rose to 20.7%.
6 min readGeron (GERN) reported Q2 2026 results, citing RYTELO (imetelstat) net product revenue of $57.5M, up 17% YoY. Net loss was $16.7M, slightly wider than $16.4M. Cash and marketable securities totaled $327M at June 30. For FY 2026, Geron guided RYTELO revenue of $220M to $240M and operating expenses of $230M to $240M. Wedbush reiterated an outperform rating and set a $6 price target.
4 min readGERON CORP (GERN) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 d158179dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Geron Corporation Reports Second Quarter 2026 Financial Results and Recent Business Highlights August 5, 2026 Achieved $57.5 million in RYTELO ® (imetelstat) net product revenue in Q2 2026, an increase of 11% compared to Q1
6 min readGeron (GERN) reported Q2 2026 net revenue of $57.5 million, up 17% year over year and 11% sequentially, driven by RYTELO sales momentum. The company reiterated 2026 net product revenue guidance of $220 million to $240 million and total operating expense guidance of $230 million to $240 million. Cash was $327 million as of June 30, 2026.
6 min readBiotech stocks rose as several companies reported updates. Attovia Therapeutics (ATTO) jumped over 28% after its Nasdaq debut at $17 and a close at $21.90. American Well (AMWL) gained about 25% after Q2 loss narrowed to $9.6M, though revenue fell to $52.0M. Perrigo (PRGO) swung to Q2 net income of $74.5M. UroGen (URGN) rose after Q2 revenue increased to $72.5M.
3 min readGeron Corp (NASDAQ:GERN) reported Q2 2026 earnings call updates, citing 5% demand growth for RYTELO vs Q1 and an 8% rise in prescribing accounts to about 1,575 since launch. Full-year revenue guidance is $220 million to $240 million, with gross-to-net deductions at 20.7% in Q2. The company is evaluating changes to an interim analysis event threshold for its IMPACT MF trial.
6 min readGeron Corporation reported Q2 2026 results on its RYTELO business, citing 17% year-over-year net revenue growth and 24% net revenue growth in the first half of 2026 with total operating expenses down 4%. Full-year 2026 RYTELO net revenue guidance is $220M to $240M. Cash was $327M. Operating expenses guidance is $230M to $240M.
4 min readThe article lists 10 “fastest growing” tech penny stocks under $5, using a Finviz screen for over 50% compounded annual revenue growth in 3 years and recent catalysts. It highlights PowerFleet (NASDAQ:AIOT) launching SafeGuard, reporting up to 83% on-road risk reduction, and approving a $30M repurchase. It also covers Geron (NASDAQ:GERN) granting 690,000 options at $1.23.
7 min readBragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Geron ( GERN ) To Contact Him Directly To Discuss Their Options
3 min readFOSTER CITY, Calif., Oct. 13, 2025 ( GLOBE NEWSWIRE ) -- Geron Corporation ( NASDAQ:GERN ) , a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced several executive transitions and appointments designed to align the company's ...
2 min read
